Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$13.93
At close: May 28 EDT
$14.08
0.151.08%
Pre-Market: 4:17 AM EDT
Comments
Loading...
Viridian Therapeutics Analyst Ratings and Price Targets | NASDAQ:VRDN | Benzinga
Viridian Therapeutics Inc has a consensus price target of $38.75 based on the ratings of 19 analysts. The high is $61 issued by BTIG on September 26, 2024. The low is $20 issued by B. Riley Securities on May 9, 2024. The 3 most-recent analyst ratings were released by Needham, RBC Capital, and Goldman Sachs on May 20, 2025, May 7, 2025, and May 7, 2025, respectively. With an average price target of $36 between Needham, RBC Capital, and Goldman Sachs, there's an implied 155.68% upside for Viridian Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Needham
RBC Capital
Goldman Sachs
JMP Securities
HC Wainwright & Co.
1calculated from analyst ratings
Analyst Ratings for Viridian Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/20/2025 | Buy Now | 155.68% | Needham | Serge Belanger66% | $36 → $36 | Reiterates | Buy → Buy | Get Alert |
| 05/07/2025 | Buy Now | 219.6% | RBC Capital | Michael Carroll62% | $46 → $45 | Maintains | Outperform | Get Alert |
| 05/07/2025 | Buy Now | 91.76% | Goldman Sachs | Richard Law46% | $31 → $27 | Maintains | Buy | Get Alert |
| 05/07/2025 | Buy Now | 169.89% | JMP Securities | Jason Butler51% | $42 → $38 | Maintains | Market Outperform | Get Alert |
| 05/07/2025 | Buy Now | 155.68% | Needham | Serge Belanger66% | $38 → $36 | Maintains | Buy | Get Alert |
| 04/23/2025 | Buy Now | 141.48% | HC Wainwright & Co. | Douglas Tsao51% | $34 → $34 | Reiterates | Buy → Buy | Get Alert |
| 01/07/2025 | Buy Now | 169.89% | Needham | Serge Belanger66% | $38 → $38 | Reiterates | Buy → Buy | Get Alert |
| 12/19/2024 | Buy Now | 91.76% | Wells Fargo | Derek Archila58% | → $27 | Downgrade | Overweight → Equal-Weight | Get Alert |
| 12/17/2024 | Buy Now | 233.81% | RBC Capital | Gregory Renza49% | $44 → $47 | Maintains | Outperform | Get Alert |
| 12/17/2024 | Buy Now | 141.48% | HC Wainwright & Co. | Douglas Tsao51% | $34 → $34 | Reiterates | Buy → Buy | Get Alert |
| 12/16/2024 | Buy Now | 141.48% | HC Wainwright & Co. | Douglas Tsao51% | $34 → $34 | Reiterates | Buy → Buy | Get Alert |
| 12/05/2024 | Buy Now | 212.5% | RBC Capital | Gregory Renza49% | $44 → $44 | Reiterates | Outperform → Outperform | Get Alert |
| 11/25/2024 | Buy Now | 169.89% | Needham | Serge Belanger66% | $38 → $38 | Reiterates | Buy → Buy | Get Alert |
| 11/25/2024 | Buy Now | — | TD Cowen | Joseph Thome26% | — | Initiates | → Buy | Get Alert |
| 11/14/2024 | Buy Now | 141.48% | HC Wainwright & Co. | Douglas Tsao51% | $27 → $34 | Maintains | Buy | Get Alert |
| 11/13/2024 | Buy Now | 169.89% | Needham | Serge Belanger66% | $38 → $38 | Reiterates | Buy → Buy | Get Alert |
| 10/28/2024 | Buy Now | 169.89% | Needham | Serge Belanger66% | $38 → $38 | Reiterates | Buy → Buy | Get Alert |
| 09/26/2024 | Buy Now | 333.24% | BTIG | Julian Harrison37% | $56 → $61 | Maintains | Buy | Get Alert |
| 09/19/2024 | Buy Now | 212.5% | RBC Capital | Gregory Renza49% | $44 → $44 | Reiterates | Outperform → Outperform | Get Alert |
| 09/13/2024 | Buy Now | 212.5% | RBC Capital | Gregory Renza49% | $35 → $44 | Maintains | Outperform | Get Alert |
| 09/12/2024 | Buy Now | 120.17% | Goldman Sachs | Richard Law46% | $25 → $31 | Maintains | Buy | Get Alert |
| 09/11/2024 | Buy Now | 169.89% | Needham | Serge Belanger66% | $30 → $38 | Maintains | Buy | Get Alert |
| 09/10/2024 | Buy Now | 91.76% | HC Wainwright & Co. | Douglas Tsao51% | $27 → $27 | Reiterates | Buy → Buy | Get Alert |
| 09/10/2024 | Buy Now | 297.73% | BTIG | Julian Harrison37% | $46 → $56 | Maintains | Buy | Get Alert |
| 08/30/2024 | Buy Now | 113.07% | Needham | Serge Belanger66% | $30 → $30 | Reiterates | Buy → Buy | Get Alert |
| 08/28/2024 | Buy Now | 148.58% | RBC Capital | Gregory Renza49% | $35 → $35 | Reiterates | Outperform → Outperform | Get Alert |
| 08/15/2024 | Buy Now | 91.76% | HC Wainwright & Co. | Douglas Tsao51% | $27 → $27 | Reiterates | Buy → Buy | Get Alert |
| 08/12/2024 | Buy Now | 98.86% | Oppenheimer | Leland Gershell67% | $31 → $28 | Reiterates | Outperform → Outperform | Get Alert |
| 07/29/2024 | Buy Now | 198.3% | Wedbush | Laura Chico49% | $42 → $42 | Reiterates | Outperform → Outperform | Get Alert |
| 07/16/2024 | Buy Now | 91.76% | HC Wainwright & Co. | Douglas Tsao51% | $27 → $27 | Reiterates | Buy → Buy | Get Alert |
| 06/11/2024 | Buy Now | — | Wolfe Research | Andy Chen39% | — | Initiates | → Outperform | Get Alert |
| 06/11/2024 | Buy Now | 113.07% | Needham | Serge Belanger66% | $30 → $30 | Reiterates | Buy → Buy | Get Alert |
| 06/06/2024 | Buy Now | 63.35% | Goldman Sachs | Richard Law46% | → $23 | Initiates | → Buy | Get Alert |
| 05/09/2024 | Buy Now | 113.07% | Needham | Serge Belanger66% | $30 → $30 | Reiterates | Buy → Buy | Get Alert |
| 05/09/2024 | Buy Now | 91.76% | HC Wainwright & Co. | Douglas Tsao51% | $37 → $27 | Maintains | Buy | Get Alert |
| 05/09/2024 | Buy Now | 120.17% | Oppenheimer | Leland Gershell67% | $36 → $31 | Maintains | Outperform | Get Alert |
| 05/09/2024 | Buy Now | — | Ladenburg Thalmann | Michael Higgins45% | — | Downgrade | Buy → Neutral | Get Alert |
| 05/09/2024 | Buy Now | 42.05% | B. Riley Securities | Kalpit Patel40% | $25 → $20 | Downgrade | Buy → Neutral | Get Alert |
| 03/21/2024 | Buy Now | 77.56% | B. Riley Securities | Kalpit Patel40% | $29 → $25 | Maintains | Buy | Get Alert |
| 03/20/2024 | Buy Now | 113.07% | Needham | Serge Belanger66% | $30 → $30 | Maintains | Buy | Get Alert |
| 02/29/2024 | Buy Now | 162.78% | HC Wainwright & Co. | Douglas Tsao51% | $37 → $37 | Reiterates | Buy → Buy | Get Alert |
| 02/28/2024 | Buy Now | 113.07% | Needham | Serge Belanger66% | $30 → $30 | Reiterates | Buy → Buy | Get Alert |
| 02/28/2024 | Buy Now | 184.09% | Wedbush | Laura Chico49% | $39 → $40 | Maintains | Outperform | Get Alert |
| 12/19/2023 | Buy Now | 155.68% | Oppenheimer | Leland Gershell67% | $35 → $36 | Maintains | Outperform | Get Alert |
| 12/18/2023 | Buy Now | 162.78% | HC Wainwright & Co. | Douglas Tsao51% | $37 → $37 | Reiterates | Buy → Buy | Get Alert |
| 12/14/2023 | Buy Now | 148.58% | RBC Capital | Gregory Renza49% | $35 → $35 | Reiterates | Outperform → Outperform | Get Alert |
| 12/04/2023 | Buy Now | 162.78% | Wedbush | Laura Chico49% | → $37 | Reiterates | Outperform → Outperform | Get Alert |
| 11/14/2023 | Buy Now | 148.58% | RBC Capital | Gregory Renza49% | → $35 | Reiterates | Outperform → Outperform | Get Alert |
| 11/14/2023 | Buy Now | 169.89% | JMP Securities | Jason Butler51% | $42 → $38 | Maintains | Market Outperform | Get Alert |
| 10/31/2023 | Buy Now | 148.58% | RBC Capital | Gregory Renza49% | $44 → $35 | Maintains | Outperform | Get Alert |
| 10/31/2023 | Buy Now | 162.78% | Wedbush | Laura Chico49% | $46 → $37 | Maintains | Outperform | Get Alert |
| 10/30/2023 | Buy Now | 113.07% | Needham | Serge Belanger66% | $40 → $30 | Maintains | Buy | Get Alert |
| 09/13/2023 | Buy Now | 184.09% | Stifel | Alex Thompson41% | → $40 | Reiterates | Buy → Buy | Get Alert |
| 09/13/2023 | Buy Now | 226.7% | Wedbush | Laura Chico49% | → $46 | Reiterates | Outperform → Outperform | Get Alert |
| 08/10/2023 | Buy Now | 162.78% | HC Wainwright & Co. | Douglas Tsao51% | $40 → $37 | Maintains | Buy | Get Alert |
| 08/10/2023 | Buy Now | 184.09% | Needham | Serge Belanger66% | $47 → $40 | Maintains | Buy | Get Alert |
| 08/09/2023 | Buy Now | 198.3% | JMP Securities | Jason Butler51% | $44 → $42 | Maintains | Market Outperform | Get Alert |
| 08/09/2023 | Buy Now | 212.5% | RBC Capital | Gregory Renza49% | → $44 | Reiterates | Outperform → Outperform | Get Alert |
| 08/09/2023 | Buy Now | 176.99% | Wells Fargo | — | $46 → $39 | Maintains | Overweight | Get Alert |
| 08/09/2023 | Buy Now | 148.58% | Oppenheimer | Leland Gershell67% | $40 → $35 | Maintains | Outperform | Get Alert |
| 07/11/2023 | Buy Now | 219.6% | Wedbush | Laura Chico49% | $48 → $45 | Maintains | Outperform | Get Alert |
| 07/11/2023 | Buy Now | 212.5% | RBC Capital | Gregory Renza49% | → $44 | Reiterates | Outperform → Outperform | Get Alert |
| 07/11/2023 | Buy Now | 212.5% | JMP Securities | Jason Butler51% | → $44 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 07/11/2023 | Buy Now | 233.81% | Needham | Serge Belanger66% | → $47 | Reiterates | Buy → Buy | Get Alert |
| 07/11/2023 | Buy Now | 184.09% | HC Wainwright & Co. | Douglas Tsao51% | → $40 | Reiterates | Buy → Buy | Get Alert |
| 06/14/2023 | Buy Now | 226.7% | BTIG | Julian Harrison37% | → $46 | Initiates | → Buy | Get Alert |
| 06/14/2023 | Buy Now | 262.22% | Credit Suisse | Tiago Fauth44% | → $51 | Assumes | → Outperform | Get Alert |
| 05/30/2023 | Buy Now | 212.5% | RBC Capital | Gregory Renza49% | → $44 | Initiates | → Outperform | Get Alert |
| 05/10/2023 | Buy Now | 184.09% | Oppenheimer | Leland Gershell67% | $45 → $40 | Maintains | Outperform | Get Alert |
| 05/10/2023 | Buy Now | 240.91% | Wedbush | Laura Chico49% | $46 → $48 | Maintains | Outperform | Get Alert |
| 05/10/2023 | Buy Now | 262.22% | Credit Suisse | Tiago Fauth44% | → $51 | Reiterates | → Outperform | Get Alert |
| 05/10/2023 | Buy Now | 212.5% | JMP Securities | Jason Butler51% | $46 → $44 | Maintains | Market Outperform | Get Alert |
| 05/10/2023 | Buy Now | 184.09% | HC Wainwright & Co. | Douglas Tsao51% | → $40 | Reiterates | → Buy | Get Alert |
| 04/17/2023 | Buy Now | 226.7% | Wells Fargo | — | → $46 | Initiates | → Overweight | Get Alert |
| 04/10/2023 | Buy Now | 233.81% | Needham | Serge Belanger66% | → $47 | Reiterates | → Buy | Get Alert |
| 03/30/2023 | Buy Now | 248.01% | Stifel | Alex Thompson41% | → $49 | Initiates | → Buy | Get Alert |
| 03/09/2023 | Buy Now | 184.09% | Ladenburg Thalmann | Michael Higgins45% | → $40 | Reiterates | → Buy | Get Alert |
| 03/09/2023 | Buy Now | 184.09% | HC Wainwright & Co. | Douglas Tsao51% | $35 → $40 | Maintains | Buy | Get Alert |
| 02/07/2023 | Buy Now | 148.58% | HC Wainwright & Co. | Douglas Tsao51% | → $35 | Reiterates | → Buy | Get Alert |
| 01/09/2023 | Buy Now | 219.6% | SVB Leerink | Thomas Smith33% | $40 → $45 | Maintains | Outperform | Get Alert |
| 12/19/2022 | Buy Now | 219.6% | Needham | Serge Belanger66% | → $45 | Initiates | → Buy | Get Alert |
| 12/16/2022 | Buy Now | 262.22% | Credit Suisse | Tiago Fauth44% | → $51 | Initiates | → Outperform | Get Alert |
| 12/01/2022 | Buy Now | 148.58% | HC Wainwright & Co. | Douglas Tsao51% | → $35 | Initiates | → Buy | Get Alert |
| 11/15/2022 | Buy Now | 226.7% | JMP Securities | Jason Butler51% | $47 → $46 | Maintains | Market Outperform | Get Alert |
| 08/16/2022 | Buy Now | 184.09% | Ladenburg Thalmann | Michael Higgins45% | $33 → $40 | Maintains | Buy | Get Alert |
| 08/15/2022 | Buy Now | 184.09% | SVB Leerink | Mike Kratky66% | $32 → $40 | Maintains | Outperform | Get Alert |
| 06/23/2022 | Buy Now | 77.56% | B. Riley Securities | Kalpit Patel40% | → $25 | Initiates | → Buy | Get Alert |
FAQ
What is the target price for Viridian Therapeutics (VRDN) stock?
The latest price target for Viridian Therapeutics (NASDAQ:VRDN) was reported by Needham on May 20, 2025. The analyst firm set a price target for $36.00 expecting VRDN to rise to within 12 months (a possible 155.68% upside). 33 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Viridian Therapeutics (VRDN)?
The latest analyst rating for Viridian Therapeutics (NASDAQ:VRDN) was provided by Needham, and Viridian Therapeutics reiterated their buy rating.
When was the last upgrade for Viridian Therapeutics (VRDN)?
There is no last upgrade for Viridian Therapeutics
When was the last downgrade for Viridian Therapeutics (VRDN)?
The last downgrade for Viridian Therapeutics Inc happened on December 19, 2024 when Wells Fargo changed their price target from N/A to $27 for Viridian Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Viridian Therapeutics (VRDN)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Viridian Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Viridian Therapeutics was filed on May 20, 2025 so you should expect the next rating to be made available sometime around May 20, 2026.
Is the Analyst Rating Viridian Therapeutics (VRDN) correct?
While ratings are subjective and will change, the latest Viridian Therapeutics (VRDN) rating was a reiterated with a price target of $36.00 to $36.00. The current price Viridian Therapeutics (VRDN) is trading at is $14.08, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
